CRBP Corbus Pharmaceuticals Holdings Inc
Price (delayed)
$5.2
Market cap
$63.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.68
Enterprise value
$48.98M
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is
Highlights
CRBP's debt has dropped by 84% year-on-year and by 10% since the previous quarter
Corbus Pharmaceuticals Holdings's EPS has surged by 64% YoY and by 21% QoQ
Corbus Pharmaceuticals Holdings's net income has increased by 10% YoY but it has decreased by 3.9% from the previous quarter
The quick ratio fell by 8% QoQ
The company's equity fell by 5% QoQ
Key stats
What are the main financial stats of CRBP
Market
Valuations
Earnings
Shares outstanding
12.23M
Market cap
$63.61M
Enterprise value
$48.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$48.72M
Net income
-$40.21M
EBIT
-$38.34M
EBITDA
-$37.75M
Free cash flow
-$41.79M
Per share
Balance sheet
Liquidity
EPS
-$3.68
EPS diluted
-$3.68
Free cash flow per share
-$3.83
Book value per share
$11.69
Revenue per share
$0
TBVPS
$14.28
Total assets
$155.88M
Total liabilities
$13.45M
Debt
$3.24M
Equity
$142.43M
Working capital
$141.16M
Debt to equity
0.02
Current ratio
12.94
Quick ratio
12.67
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.9%
Return on equity
-31.2%
Return on invested capital
-31.5%
Return on capital employed
-26.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRBP stock price
How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
3.38%
1 week
-12.16%
1 month
-31.13%
1 year
-86.12%
YTD
-55.93%
QTD
-2.07%
Financial performance
How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.72M
Net income
-$40.21M
Gross margin
N/A
Net margin
N/A
Corbus Pharmaceuticals Holdings's net income has increased by 10% YoY but it has decreased by 3.9% from the previous quarter
The operating income is down by 8% year-on-year and by 5% since the previous quarter
Growth
What is Corbus Pharmaceuticals Holdings's growth rate over time
Valuation
What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
0.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has surged by 64% YoY and by 21% QoQ
CRBP's P/B is 95% below its 5-year quarterly average of 7.9 and 84% below its last 4 quarters average of 2.7
The company's equity fell by 5% QoQ
Efficiency
How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE has soared by 97% YoY and by 26% QoQ
CRBP's return on invested capital has surged by 78% year-on-year and by 23% since the previous quarter
The ROA has soared by 76% YoY and by 18% from the previous quarter
Dividends
What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRBP.
Financial health
How did Corbus Pharmaceuticals Holdings financials performed over time
CRBP's total liabilities has plunged by 62% YoY
The quick ratio fell by 8% QoQ
CRBP's debt is 98% smaller than its equity
CRBP's debt to equity has soared by 101% year-on-year
CRBP's debt has dropped by 84% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.